Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: a pilot study.
Desmopressin (1-deamino-8-d-arginine vasopressin, also known as DDAVP) is a safe haemostatic compound capable of inhibiting lymph node and lung metastasis in a mouse model of mammary tumour manipulation and surgical excision. The aim of this study was to test the efficacy and safety of perioperative DDAVP (1microg/kg) in surgically treated bitches with mammary gland tumours (MGT). Twenty-one, otherwise healthy, intact bitches, with malignant MGT stage III or IV were randomly allocated to DDAVP (n=11) or placebo (n=10) groups. En bloc mastectomy of the affected gland/s was performed. DDAVP had a significant beneficial effect on disease-free period (P<0.01) and overall survival time (P<0.05). No side effects were seen in any of the cases. Whatever the mechanism of action, it seems that DDAVP may have a novel use in cancer surgery to minimise spread or survival of residual malignant cells. Additional, large scale controlled trials are required to fully evaluate this adjuvant pharmacological protocol.
Hermo
Guillermo A
GA
Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Argentina. ghermo@unq.edu.ar
Torres
Perla
P
Ripoll
Giselle V
GV
Scursoni
Alejandra M
AM
Gomez
Daniel E
DE
Alonso
Daniel F
DF
Gobello
Cristina
C
D000818:Animals; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D005260:Female; D015674:Mammary Neoplasms, Animal / Q000628:therapy*; D010865:Pilot Projects
D003894:Deamino Arginine Vasopressin